A randomized controlled trial has started in Japan to evaluate the efficacy of extensive intraoperative peritoneal lavage in the treatment of resectable advanced gastric cancer. Patients with T3 or deeper carcinoma of the stomach are intraoperatively randomized to either extensive intraoperative peritoneal lavage þ arm or extensive intraoperative peritoneal lavage2 arm. A total of 300 patients will be accrued from 20 institutions. The primary endpoint is disease-free survival, and secondary end-points are overall survival, peritoneal recurrence-free survival and incidence of adverse events.
INTRODUCTION
Even if curatively resected, patients with T4 stage or serosapositive gastric cancer often suffer from recurrence as peritoneal dissemination, and the prognosis of those patients is extremely poor (1 -4) . Peritoneal recurrence could be caused by cancer cells that had already been shed from the serosal surface at the time of surgery, sometimes detectable by examining the peritoneal washes, or those that were disseminated during surgical procedures. It is important to eliminate the intraperitonealfree cancer cells to prevent peritoneal recurrence.
Kuramoto et al. (5) reported the result of a prospective randomized control study to evaluate the efficacy of extensive intraoperative peritoneal lavage followed by intraperitoneal chemotherapy (EIPL -IPC) in the treatment of advanced gastric cancer with intraperitoneal-free cancer cells without overt peritoneal metastasis (CYþ/P2). In this study, patients with CYþ/P2 status were randomly allocated to three groups: surgery-alone group, surgery plus IPC group and surgery plus EIPL and IPC (EIPL -IPC) group. The overall 5-year survival rate of the patients in the EIPL -IPC group (43.8%) was significantly better than that of the IPC group (4.6%) and the surgery-alone group (0%), and the EIPL -IPC group had a significantly lower incidence of peritoneal recurrence than the other groups.
Although the EIPL therapy is easy to perform, safe and inexpensive, it might practically nullify the number of intraperitoneal-free cancer cells. It is expected that the EIPL reduces the incidence of peritoneal recurrence not only among patients with CYþ/P2 status, but also in a population with curatively resected serosa-positive gastric cancer.
Based on these findings, we planned a randomized Phase III trial to compare gastrectomy plus EIPL followed by standard adjuvant chemotherapy with gastrectomy and standard adjuvant chemotherapy for macroscopically resectable gastric cancer of T3.
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OBJECTIVE
The aim of this study was to demonstrate the superiority in disease-free survival of the addition of EIPL to the standard treatment in patients with T3 carcinoma of the stomach.
STUDY SETTING
The study was a multi-institutional prospective, randomized Phase III trial, where 20 institutions are actively participating as of May 2013.
RESOURCES
Data center services are funded by a non-profit organization, the Chubu Clinical Oncology Group (CCOG), Nagoya, Japan. All treatments have been approved as a general practice within the scope of general medical insurance.
ENDPOINTS
The primary end-point is disease-free survival, and secondary end-points are overall survival, peritoneal recurrence-free survival and incidence of adverse events. 
RANDOMIZATION
The participants are to call to the CCOG Data Center by telephone during surgery after confirmation of the respectability and other criteria mentioned above. The patients are randomized to either EIPLþ arm or EIPL2 arm. The minimization method is used for randomization, balancing the arms according to the T-stage (T3/T4a/T4b), pre-operative chemotherapy (with/without) and institution.
TREATMENT METHODS
EIPL2ARM
Total or distal gastrectomy with D2 lymphadenectomy is performed according to the Japanese gastric cancer treatment guideline (7) . Peritoneal lavage is done with ,3 l of physiological saline before the closure of the abdominal wall.
EIPL1 ARM
After total or distal gastrectomy with D2 lymphadenectomy, the peritoneal cavity is extensively rinsed 10 times with 1 l physiological saline at a time, followed by complete aspiration of the fluid. In total, 10 l saline is to be used.
FOLLOW-UP
Adjuvant chemotherapy with S-1 for 1 year is recommended for patients with curative resection and pathological stage IIB, IIIA, IIIB or IIIC tumors.
Patients are seen and assessed with physical examination and analysis of tumor markers every 3 months until the second year and every 6 months until the fifth year. Abdominal and pulmonary computed tomography is carried
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EIPL for resectable advanced gastric cancer out once every 6 months until the third year and once every year until the fifth year. Upper gastrointestinal endoscopy is carried out every year until the third year. When physicians suspect peritoneal recurrences either clinically or from computed tomography findings, they are requested to attempt to confirm the diagnosis with additional imaging examination such as enteroclysis and barium enema. In the event of no significant findings, physicians will need to decide on the diagnosis clinically based on the results of all of examinations and patient's symptoms.
STUDY DESIGN AND STATISTICAL ANALYSIS
This randomized trial is designed to demonstrate that EIPLþ is superior to EIPL2 in terms of disease-free survival. The hypothesis is that the 3-year disease-free survival of EIPLþ arm is greater than that of the control (EIPL2, with estimated 3-year disease-free survival of 55%, which was assumed from the historical data of the similar cohort operated at Aichi Cancer Center Hospital between 2000 and 2004. This cohort consisted of pT3, pT4a and pT4b tumors at the proportion of 36:53:11). To ensure at least 80% power to detect the difference of 15% with a both-sided alpha of 5%, the planned sample size is 300 cases, 150 cases per arm, with 2 years of accrual and 3 years of follow-up. If a statistically significant improvement in 3-year disease-free survival is demonstrated, gastrectomy with EIPL will be the new standard treatment.
INTERIM ANALYSIS AND MONITORING
Two interim analyses are planned: the first at the time when half of the total patients are registered and the second after the completion of registration. The Data and Safety Monitoring Committee will independently review the interim analysis reports and consider whether it is necessary to stop the trial prematurely. In-house interim monitoring will be performed by the Data Center to evaluate and improve the study progress and quality.
UMIN CLINICAL TRIALS REGISTRY
This trial was registered at the UMIN Clinical Trials Registry as UMIN000005907 (http://www.umin.ac.jp/ctr/index.htm) and was activated on 8 July 2011.
